Silke Gillessen Sommer presents the phase III PEACE-3 trial results, which evaluated the combination of radium-223 and enzalutamide in asymptomatic or mildly symptomatic patients with bone mCRPC. The ...

The predictive value of prostate spherical volume ratio in lower urinary tract symptoms and clinical progression of benign prostatic hyperplasia: a retrospective cohort study. BPH - Benign Prostatic ...

The advent of PSMA-based PET imaging has brought a transformative shift in the personalized management of prostate cancer (PCa), with increasing routine clinical utilization across different stages of ...

Avelumab, an anti-programmed death ligand 1 antibody, was approved in combination with axitinib for curatively unresectable or metastatic renal cell carcinoma (RCC) in Japan in December 2019. Because ...

To investigate the expression of metabolism-related genes (MRGs) in kidney renal clear cell carcinoma (KIRC) and their association with patient prognosis, and to identify potential targets for ...

Patient stratification remains a challenge for optimal treatment of prostate cancer (PCa). This clinical heterogeneity implies intra-tumoural heterogeneity, with different prostate epithelial cell ...

Non-muscle-invasive Bladder Cancer (NMIBC) is notorious for its high recurrence rate of 70-80%, imposing a significant human burden and making it one of the costliest cancers to manage. Current ...

Accurate grading and staging of non-muscle invasive bladder cancer (NMIBC) is critical for prognosis and treatment selection. The advent of digital pathology and artificial intelligence (AI) has ...

Gautam Jayram discusses key updates in bladder and kidney cancer management. Topics include intermediate-risk bladder cancer, BCG-unresponsive disease, immunotherapy for muscle-invasive bladder cancer ...

This article provides a comprehensive overview of the current treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) following the failure of first-line therapy.

The 18-gene MyProstateScore 2.0 (MPS2) test was previously validated for detection of Grade Group≥2 (GG≥2) prostate cancer using post-digital rectal examination (DRE) urine. To improve ease of testing ...

The highly specialized language used in prostate biopsy pathology reports coupled with low rates of health literacy leave some patients unable to comprehend their medical information. Patients' use of ...